FDA approves Swiss dermatological company Galderma’s AKLIEF acne cream
Category: #health  By Saipriya Iyer  Date: 2019-10-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA approves Swiss dermatological company Galderma’s AKLIEF acne cream

Skin care is one of the fastest growing concerns of the modern generation and acne is the foremost issue many face in their day-to-day lives. Global pharmaceutical firms are increasingly working towards finding treatments for skin care and reduce acne issues for people.

Galderma S.A., a renowned Swiss pharmaceutical firm specializing in the development, research and marketing of dermatological therapies, reportedly announced that the United States Food and Drug Administration (FDA) granted approval to its AKLIEF® Cream (trifarotene), 0.005% for acne’s topical treatment.

AKLIEF Cream is a unique topical retinoid that targets RAR (retinoic acid receptor) gamma, the RAR that is most commonly found in the skin, selectively. Trifarotene is now the first novel retinoid molecule, which has received U.S. FDA approval to treat acne, since the last 20 years.

AKLIEF Cream is the first and only topical therapy that has been specifically studied and proven for the treatment of facial (chin, nose, cheeks and forehead) as well as truncal (back, shoulders and chest) acne, providing acne patients and healthcare professionals another option for acne treatment.

The AKLIEF Cream approval by FDA is supported by data received from two pivotal Phase 3 clinical studies of daily-once AKLIEF Cream applied on patients having moderate acne on the trunk and face.    

An investigator at the clinical studies of AKLIEF Cream as well as a dermatologist at the Johnson Dermatology in Fort Smith, Arkansas, Sandra Johnson, M.D., FAAD, stated that retinoids are foundational treatments to treat acne, but there has been very little innovation in this field in decades. 

Johnson added that with the FDA approval for AKLIEF Cream, it would be quite thrilling to offer the patients a highly targeted, unique retinoid that decreases inflammatory lesions that occur on the back, face, shoulders and chest, and that has also been proven to be well-tolerated and safe.

AKLIEF Cream would be available across the United States by November 2019. The cream would be provided in a pump of 45 gram. Also, Galderma is closely working with providers, payers and pharmacy benefit managers in an effort to ensure rapid and broad access to AKLIEF C ream.

Additionally, the pharmaceutical firm would also give a patient savings card program named as Galderma CareConnect to uninsured or commercially insured patients.

 

Source credit: https://www.galderma.com/us/news/galderma-receives-fda-approval-akliefr-trifarotene-cream-0005-first-new-retinoid-molecule



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Alibaba plans to offer bitcoin rewards to shoppers through Lolli
Alibaba plans to offer bitcoin rewards to shoppers through Lolli
By Saipriya Iyer

 

  • Now Alibaba shoppers can earn free bitcoin when they purchase products on Alibaba's e-commerce platform
  • Reportedly, the partnership would enable shoppers...

Daiichi Sankyo announces positive results from Phase 3 pivotal trial
Daiichi Sankyo announces positive results from Phase 3 pivotal trial
By Saipriya Iyer

Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo), today made a breakthrough announcement stating that the main objective has been achieved from ESAX-DN—a phase 3 pivotal study of esaxerenone—a pro...

CANbridge Pharmaceuticals receives registration approval for NERLYNX®
CANbridge Pharmaceuticals receives registration approval for NERLYNX®
By Saipriya Iyer

Puma Biotechnology, Inc. has reportedly announced that its licensing partner CANbridge Pharmaceuticals Inc., based in Greater China, has secured registration approval to market NERLYNX® (neratinib) from the De...